Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Common Equity: 2017-2025

Historic Common Equity for Autolus Therapeutics (AUTL) over the last 4 years, with Sep 2025 value amounting to $265.5 million.

  • Autolus Therapeutics' Common Equity fell 44.35% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year decrease of 44.35%. This contributed to the annual value of $427.3 million for FY2024, which is 283.34% up from last year.
  • Latest data reveals that Autolus Therapeutics reported Common Equity of $265.5 million as of Q3 2025, which was down 23.38% from $346.5 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Common Equity registered a high of $582.0 million during Q1 2024, and its lowest value of $111.5 million during Q4 2023.
  • For the 3-year period, Autolus Therapeutics' Common Equity averaged around $344.1 million, with its median value being $346.5 million (2025).
  • As far as peak fluctuations go, Autolus Therapeutics' Common Equity tumbled by 62.68% in 2023, and later soared by 283.34% in 2024.
  • Quarterly analysis of 5 years shows Autolus Therapeutics' Common Equity stood at $313.3 million in 2021, then fell by 4.67% to $298.7 million in 2022, then tumbled by 62.68% to $111.5 million in 2023, then surged by 283.34% to $427.3 million in 2024, then slumped by 44.35% to $265.5 million in 2025.
  • Its Common Equity stands at $265.5 million for Q3 2025, versus $346.5 million for Q2 2025 and $371.1 million for Q1 2025.